$11.93
+0.35(3.02%)
Mkt Cap $1.5B
$5.28
$14.17
52-Week Range
At a Glance
AI-generated8-K
Trevi Therapeutics, Inc. announced results of the Company’s End-of-Phase 2 meeting with the FDA on March 9, 2026. This disclosure under Item 8.01 represents a key regulatory milestone for the Company’s development program.$1.5B
Market Cap
—
Revenue
-$38M
Net Income
Employees31
Fundamentals
How The Business Makes Money
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001563880
ISINUS89532M1018
CUSIP89532M101
Phone203 304 2499
Address195 Church Street, New Haven, CT, 06510, US
SEC EDGAR